Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HRAS Protein (His tag)

HRAS Spezies: Human Wirt: Baculovirus infected Insect Cells Recombinant > 94 % as determined by reducing SDS-PAGE.
Produktnummer ABIN7196121
  • Target Alle HRAS Proteine anzeigen
    HRAS (HRas proto-oncogene, GTPase (HRAS))
    Protein-Typ
    Recombinant
    Spezies
    • 13
    • 2
    • 2
    • 1
    • 1
    Human
    Quelle
    • 8
    • 4
    • 3
    • 2
    • 2
    Baculovirus infected Insect Cells
    Aufreinigungstag / Konjugat
    Dieses HRAS Protein ist gelabelt mit His tag.
    Verwendungszweck
    Recombinant Human HRAS/GTPase Hras Protein (His Tag)
    Sequenz
    Met 1-Cys 186
    Produktmerkmale
    A DNA sequence encoding the human HRAS (P01112) (Met 1-Cys 186) was fused with a polyhistidine tag at the C-terminus.
    Reinheit
    > 94 % as determined by reducing SDS-PAGE.
    Endotoxin-Niveau
    < 1.0 EU per μg as determined by the LAL method.
    Top Product
    Discover our top product HRAS Protein
  • Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Please refer to the printed manual for detailed information.
    Buffer
    Lyophilized from sterile 50 mM Tris, 100 mM NaCl, pH 8.0, 10 % glycerol
    Lagerung
    4 °C,-20 °C,-80 °C
    Informationen zur Lagerung
    Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
  • Target
    HRAS (HRas proto-oncogene, GTPase (HRAS))
    Andere Bezeichnung
    HRAS/GTPase Hras (HRAS Produkte)
    Synonyme
    C-BAS/HAS Protein, C-H-RAS Protein, C-HA-RAS1 Protein, CTLO Protein, H-RASIDX Protein, HAMSV Protein, HRAS1 Protein, K-RAS Protein, N-RAS Protein, RASH1 Protein, hras Protein, zgc:110250 Protein, HRAS Protein, H-RAS Protein, c-H-ras Protein, H-Ras Protein, K-Ras Protein, hras1 Protein, rash1 Protein, ras Protein, N-Ras Protein, c-bas/has Protein, H-ras Protein, Ha-ras Protein, Harvey-ras Protein, Hras-1 Protein, Kras2 Protein, c-Ha-ras Protein, c-rasHa Protein, hrasl Protein, zgc:110734 Protein, HRas proto-oncogene, GTPase Protein, v-Ha-ras Harvey rat sarcoma viral oncogene homolog a Protein, neuroblastoma RAS viral (v-ras) oncogene homolog pseudogene Protein, Harvey rat sarcoma viral oncogene homolog L homeolog Protein, Harvey rat sarcoma viral oncogene homolog Protein, Harvey rat sarcoma virus oncogene Protein, NRAS proto-oncogene, GTPase Protein, -Ha-ras Harvey rat sarcoma viral oncogene homolog b Protein, HRAS Protein, hrasa Protein, LOC733587 Protein, Hras Protein, hras.L Protein, hras Protein, NRAS Protein, hrasb Protein
    Hintergrund

    Background: HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    Synonym: C-BAS/HAS;C-H-RAS;C-HA-RAS1;CTLO;H-RASIDX;HAMSV;HRAS1;p21ras;RASH1

    Molekulargewicht
    22.4 kDa
    UniProt
    P01112
    Pathways
    p53 Signalweg, MAPK Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Hepatitis C, Autophagie, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling, BCR Signaling
Sie sind hier: